Abstract:PurposeAminopeptidase N (APN/CD13) is highly expressed on the surface of cancer cells and is thought to be involved in cancer growth and metastasis. The research of APN/CD13 inhibitors is considered as a strategy of cancer treatment. We aimed to evaluate the efficacy of CIP-13F, a novel APN/CD13 inhibitor, using a Lewis lung carcinoma (LLC) implantation mouse model.MethodsC57BL/6 mice were subcutaneously inoculated with LLC cells in anterior flank. Then, 0, 50 and 100 mg/kg of CIP-13F were injected via vena caudalis. Bestatin was used as the positive control. Administration of CIP-13F or bestatin was performed daily for 3 consecutive weeks. Mice were killed, and the tumors in anterior flank and metastasis nodules in lungs were examined. The assays of immunohistochemical staining, immunofluorescent flow cytometry and western blotting were performed to estimate the expression of APN/CD13 in LLC cells. We carried out the experiments of Annexin-V/PI staining, DNA fragmentation analysis and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining to determine apoptotic cells in LLC tissues. Using immunohistochemical staining with CD34, the antiangiogenesis of CIP-13F was evaluated in LLC tissue sections.ResultsCIP-13F treatment resulted in a significant delay of LLC growth in anterior flank. Examination of lungs showed that the number of metastatic nodules of LLC was also markedly decreased. The inhibitory effect of CIP-13F on LLC growth was further evidenced by the induction of LLC apoptosis, showing the increases in Annexin-V/PI staining cells, DNA fragmentation and TUNEL staining cells. Molecular analyses of LLC tissues in CIP-13F-treated mice suggested that the decrease in APN/CD13 expression by CIP-13F might account for its actions of mechanism. Further, the inhibition of angiogenesis in LLC tissues was determined, showing the decreases in microvessel density (MVD) and angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor-alpha (TGF-α).ConclusionOur results showed that CIP-13F effectively inhibited LLC growth and pulmonary metastasis in mice and suggested that CIP-13F is a potential drug for the treatment for cancers with positive APN/CD13 expression.

Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells.

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Design, synthesis and preliminary activity evaluation of novel 3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as aminopeptidase N/CD13 inhibitors.

Novel Aminopeptidase N (APN/CD13) Inhibitors Derived from 3-Phenylalanyl-n'-substituted-2,6-piperidinedione.

13F-1, a Novel 5-Fluorouracil Prodrug Containing an Asn–Gly–Arg (NO2) COOCH3 Tripeptide, Inhibits Human Colonic Carcinoma Growth by Targeting Aminopeptidase N (APN/CD13)

Activity Screening and Structure-Activity Relationship of the Hit Compounds Targeting Apn/Cd13

Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.

Novel Aminopeptidase N (APN/CD13) Inhibitor 24F Can Suppress Invasion of Hepatocellular Carcinoma Cells As Well As Angiogenesis.

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Amino Acid Ureido Derivatives As Aminopeptidase N/CD13 Inhibitors

Anti-tumor Targeted Drug Delivery Systems Mediated by Aminopeptidase N/CD13

Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design.

Novel indoline-2,3-dione derivatives as inhibitors of aminopeptidase N (APN).

Antitumor Activity of Antimicrobial Peptides Containing CisoDGRC in CD13 Negative Breast Cancer Cells

Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers

The Role of the Ectopeptidase APN/CD13 in Cancer

Novel Leucine Ureido Derivatives As Inhibitors of Aminopeptidase N (APN).

Aminopeptidase N Inhibitor 4cc Synergizes Antitumor Effects of 5-Fluorouracil on Human Liver Cancer Cells Through ROS-dependent CD13 Inhibition.

Design,synthesis and Bioactivity Evalution of N-substituted-2,6-dioxopiperidin Derivatives As Aminopeptidase N(APN/CD13) Inhibitors

Inhibiting Effects of a Cyclic Peptide CNGRC on Proliferation and Migration of Tumor Cells In Vitro

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.